Biomarker-Guided HF Therapy: Is It Cost-Effective?

1
Biomarker-Guided HF TherapyIs It Cost-Effective?
2
Age-Adjusted Hospitalization Rates for Heart
Failure
3
Cost of Heart Failure to Society
4
Diagnostic Uncertainty Is Associated With Poor
Prognosis in Acute Dyspnea
5
(No Transcript)
6
Effect of Selective NT-proBNP Testing on
CostsResults of the Randomized IMPROVE-CHF Trial
7
ADHERE Time From BNP to Time to Diuretic
Treatment
8
OPTIMIZE-HF BNP Measures and Death and
Hospitalization at 1 Year
9
Therapies With Effects on B-Type Natriuretic
Peptide Levels
10
IMPROVE HF Improvement in Quality Measures at 24
Months (Patient Level Analysis)
11
PROTECT Primary Endpoint Reduction
12
Cost-Effectiveness TIME-CHF Mortality in Reduced
LVEF
13
Biomarker -Guided Heart Failure Trials
14
GUIDE-IT
15
Challenges/Opportunities for Utilizing Biomarkers
in the Management of Heart Failure
16
Thank you for joining us for this program. So,
what would you do? What impact does this program
on biomarkers have on your practice? As a
reminder please join me on Medscape Discuss, a
supplementary discussion by clicking the Join the
Discussion  button now. I am interested in
hearing your thoughts and questions around this
topic.
17
(No Transcript)
18
(No Transcript)